Literature DB >> 8460106

Effect of end group blockage on the properties of a class A amphipathic helical peptide.

Y V Venkatachalapathi1, M C Phillips, R M Epand, R F Epand, E M Tytler, J P Segrest, G M Anantharamaiah.   

Abstract

In a recent classification of biologically active amphipathic alpha-helixes, the lipid-associating domains in exchangeable plasma apolipoproteins have been classified as class A amphipathic helixes (Segrest, J.P., De Loof, H., Dohlman, J.G., Brouillette, C.G., Anantharamaiah, G.M. Proteins 8:103-117, 1990). A model peptide analog with the sequence, Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu Ala Phe (18A), possesses the characteristics of a class A amphipathic helix. The addition of an acetyl group at the alpha-amino terminus and an amide at the alpha-carboxyl terminus, to obtain Ac-18A-NH2, produces large increases in helicity for the peptide both in solution and when associated with lipid (for 18A vs Ac-18A-NH2, from 6 to 38% helix in buffer and from 49 to 92% helix when bound to dimyristoyl phosphatidylcholine in discoidal complexes). Blocking of the end-groups of 18A stabilizes the alpha-helix in the presence of lipid by approximately 1.3 kcal/mol. There is also an increase in the self-association of the blocked peptide in aqueous solution. The free energy of binding to the PC-water interface is increased only by about 3% (from -8.0 kcal/mol for 18A to -8.3 kcal/mol for Ac-18A-NH2). The Ac-18A-NH2 has a much greater potency in raising the bilayer to hexagonal phase transition temperature of dipalmitoleoyl phosphatidylethanolamine than does 18A. In this regard Ac-18A-NH2 more closely resembles the behavior of the apolipoprotein A-I, which is the major protein component of high-density lipoprotein and a potent inhibitor of lipid hexagonal phase formation. The activation of the plasma enzyme lecithin: cholesterol acyltransferase by the Ac-18A-NH2 peptide is greater than the 18A analog and comparable to that observed with the apo A-I. In the case of Ac-18A-NH2, the higher activating potency may be due, at least in part, to the ability of the peptide to micellize egg PC vesicles.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8460106     DOI: 10.1002/prot.340150403

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  31 in total

1.  Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice.

Authors:  Gaurav Nayyar; David W Garber; Mayakonda N Palgunachari; Candyce E Monroe; Tamara D Keenum; Shaila P Handattu; Vinod K Mishra; G M Anantharamaiah
Journal:  Atherosclerosis       Date:  2012-06-23       Impact factor: 5.162

Review 2.  HDL therapy for cardiovascular diseases: the road to HDL mimetics.

Authors:  C Roger White; Geeta Datta; Zhenghao Zhang; Himanshu Gupta; David W Garber; Vinod K Mishra; Mayakonda N Palgunachari; Shaila P Handattu; Manjula Chaddha; G M Anantharamaiah
Journal:  Curr Atheroscler Rep       Date:  2008-10       Impact factor: 5.113

3.  Peptide Mimetics of Apolipoproteins Improve HDL Function.

Authors:  Mohamad Navab; G M Anantharamaiah; Srinivasa T Reddy; Brian J Van Lenten; Georgette M Buga; Alan M Fogelman
Journal:  J Clin Lipidol       Date:  2007-05       Impact factor: 4.766

4.  Amyloidogenic Mutation Promotes Fibril Formation of the N-terminal Apolipoprotein A-I on Lipid Membranes.

Authors:  Chiharu Mizuguchi; Fuka Ogata; Shiho Mikawa; Kohei Tsuji; Teruhiko Baba; Akira Shigenaga; Toshinori Shimanouchi; Keiichiro Okuhira; Akira Otaka; Hiroyuki Saito
Journal:  J Biol Chem       Date:  2015-07-14       Impact factor: 5.157

Review 5.  Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins.

Authors:  Satoshi Imaizumi; Mohamad Navab; Cecilia Morgantini; Christina Charles-Schoeman; Feng Su; Feng Gao; Murray Kwon; Ekambaram Ganapathy; David Meriwether; Robin Farias-Eisner; Alan M Fogelman; Srinivasa T Reddy
Journal:  Circ J       Date:  2011-05-28       Impact factor: 2.993

Review 6.  Multiple indications for anti-inflammatory apolipoprotein mimetic peptides.

Authors:  Brian J Van Lenten; Mohamad Navab; G M Anantharamaiah; Georgette M Buga; Srinivasa T Reddy; Alan M Fogelman
Journal:  Curr Opin Investig Drugs       Date:  2008-11

7.  Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.).

Authors:  C Roger White; Geeta Datta; Paulina Mochon; Zhenghao Zhang; Ollie Kelly; Christine Curcio; Dale Parks; Mayakonda Palgunachari; Shaila Handattu; Himanshu Gupta; David W Garber; G M Anantharamaiah
Journal:  Vasc Dis Prev       Date:  2009-01-01

Review 8.  Structure and function of HDL mimetics.

Authors:  Mohamad Navab; Ishaiahu Shechter; G M Anantharamaiah; Srinivasa T Reddy; Brian J Van Lenten; Alan M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-07-16       Impact factor: 8.311

9.  Oxpholipin 11D: an anti-inflammatory peptide that binds cholesterol and oxidized phospholipids.

Authors:  Piotr Ruchala; Mohamad Navab; Chun-Ling Jung; Susan Hama-Levy; Ewa D Micewicz; Hai Luong; Jonathan E Reyles; Shantanu Sharma; Alan J Waring; Alan M Fogelman; Robert I Lehrer
Journal:  PLoS One       Date:  2010-04-14       Impact factor: 3.240

Review 10.  HDL as a biomarker, potential therapeutic target, and therapy.

Authors:  Mohamad Navab; G M Anantharamaiah; Srinivasa T Reddy; Brian J Van Lenten; Alan M Fogelman
Journal:  Diabetes       Date:  2009-12       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.